Genetically distinct viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have been recorded since January 2020. Over this time global vaccine programs …

Background The immune profile against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has dramatically diversified due to a complex combination of exposure to …

Background SARS-CoV-2 vaccines currently authorized for emergency use have been
highly successful in preventing infection and lessening disease severity. The vaccines …

The SARS-CoV-2 Omicron variant was first identified in November 2021 in Botswana and
South Africa,. It has in the meantime spread to many countries and is expected to rapidly …

Background Genetically distinct viral variants of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been recorded since January 2020. The introduction of …

Omicron has become the globally dominant severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade …

Introduction The evolution of novel SARS-CoV-2 variants significantly affects vaccine
effectiveness. While these effects can only be studied retrospectively, neutralizing antibody …

On December 23, 2021, five groups published their research results of clinical-approved
monoclonal antibodies, convalescent serum, and vaccine serum against B. 1.1. 529 …

Summary Background The SARS-CoV-2 omicron (B. 1.1. 529) variant, which was first
identified in November, 2021, spread rapidly in many countries, with a spike protein highly …

In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.
1.1. 529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in …